that the doubt has been made public [3]. Jan Hendriks, for example, who developed the Dutch screening programme, has recently declared [4] that if the mortality from breast cancer has not declined drastically in 2003, the nationwide screening programme should be stopped.

The picture is confusing

In Sweden the picture is also confusing. Based on the Swedish screening trials it was predicted that a substantial decline in breast cancer mortality would be seen around the turn of the century, but last summer Nina Rehnquist, director of the National Board of Health, admitted that it is difficult to explain the lack of a visible effect of screening [5]. Also Ingar Andersson, primary author of the Malmö screening study, expressed disappointment [5].

Nevertheless, Måns Rosén, also from the National Board of Health, continues to argue that there has been about a 30% reduction in breast cancer mortality (in accordance with the results from the Two-county study which was sponsored by the National Board of Health). Most recently the »proof» consisted of an epidemiological analysis which involved a fourth grade polynomial! [6].

Persuasive language

In the lack of good arguments, Peter Dean uses persuasive language with superlatives which, unfortunately, is all too common when the issue is breast cancer screening. He speaks about our »heavily criticized reports» in contrast to »the highly respected Swedish mammography screening trials». We then wonder why two of these highly respected trials were attacked last summer by the Swedish Medical Research Council and the Swedish Council for Technology Assessment in Health Care with allegations of scientific misconduct [7].

What everybody, and in particular all the women of this world, really need, is a critical, systematic re-evaluation of the best available evidence regarding the possible benefits and harms of breast cancer screening.

Ongoing review will contribute

Our ongoing Cochrane review on breast cancer screening with mammography [8] will contribute to this and we hope that the Swedish trialists, like trialists from the other countries we have approached, will contribute to this re-evaluation by disclosing the information needed for such a critical re-assessment.

At an international conference of the screening trialists in 1993, it was recommended that the degree to which causes of death had been reclassified in each of the Swedish studies when they were combined in a meta-analysis needed to be clarified [9]. As far as we know, this has not been achieved.

Open discussion needed

We feel, however, Sweden owes to the rest of the World to discuss this and other uncertainties openly, e.g. whether the screened and control groups were comparable at baseline and whether exclusions of randomised women led to biased assessments of benefits like we have demonstrated for the trials conducted in New York and Edinburgh [1, 3]. It is somewhat unclear what has happened in the Swedish trials. This is cause for concern and it needs to be fully addressed.

Final comment

The articles by Gøtzsche and Olsen are not official Cochrane reviews and lack scientific merit

I agree with the authors that »a scientific paper should be judged solely by its scientific merit». In a recent editorial, Prof N Wald stated: »Gøtzsche and Olsen’s paper lacks scientific merit» and »The Lancet should not have published this paper» [1]. Although the authors claim to have »used Cochrane principles», according to Dr C Hyde of the Cochrane Collaboration, they failed to follow 10 important appraisal criteria for reviews [2].

Of the eleven published responses in The Lancet, »All but one correspondent disagreed with the conclusions of the study» [3]. The accompanying Commentary criticized their paper [4].

No confusion in Sweden

It is not true that two Swedish insti-...